Download PDF
CC BY 4.0 · Brazilian Journal of Oncology 2024; 20: s00441790563
DOI: 10.1055/s-0044-1790563
Original Article
Surgical Oncology

Postchemotherapy Robot-Assisted Retroperitoneal Lymph Node Dissection for Metastatic Testicular Cancer: Initial Experience at a Brazilian Oncology Center

Tadeu José Fontenele Leite Campos 
1   Urology Division, Instituto Nacional de Câncer (INCA), Rio de Janeiro, RJ, Brazil.
,
Felipe Monerrat Lott 
1   Urology Division, Instituto Nacional de Câncer (INCA), Rio de Janeiro, RJ, Brazil.
,
Jan Michael Sobel
1   Urology Division, Instituto Nacional de Câncer (INCA), Rio de Janeiro, RJ, Brazil.
,
Walter Carlos Oliveira 
1   Urology Division, Instituto Nacional de Câncer (INCA), Rio de Janeiro, RJ, Brazil.
,
Franz Santos Campos
1   Urology Division, Instituto Nacional de Câncer (INCA), Rio de Janeiro, RJ, Brazil.
› Author Affiliations Funding The authors declare that they did not receive funding from agencies in the public, private or non-profit sectors to conduct the present study.
› Further Information
   Permissions and Reprints All articles of this category

Abstract

Introduction Testicular cancer is the most common neoplasm in men aged 20 to 40 years. Retroperitoneal lymph node dissection plays an essential role in the treatment of such patients. Conventional open surgery has a complication rate of 30 to 36%. Some case series have demonstrated that a robot-assisted technique presented safety, oncological efficacy, and yielded lower complication rates. We retrospectively evaluated peri- and postoperative outcomes of robot-assisted retroperitoneal lymph node dissection after chemotherapy performed in patients at Instituto Nacional de Câncer (INCA), Rio de Janeiro, Brazil.

Materials and Methods The present study included all patients who underwent postchemotherapy robot-assisted retroperitoneal lymph node dissection for the treatment of metastatic testicular cancer at INCA.

Results From August 2020 to November 2021, 5 robot-assisted retroperitoneal lymph node dissections were performed. The mean size of the resected mass was of 7.28 cm. The mean operative time was of 307.4 minutes, and the mean length of the postoperative hospital stay was of 3.2 days. The complication rate during the first 30 days after surgery was of 0%.

Conclusion Robot-assisted retroperitoneal lymph node dissection for metastatic testicular cancer demonstrated favorable perioperative outcomes, with no readmissions or complications within 30 days. Appropriate selection of patients for this technique is crucial. A larger sample with an extended follow-up is necessary for a definitive conclusion.

Keywords

testicular neoplasms - lymph node excision - robotic surgical procedures

Author's Contributions

TJFLC: collection and assembly of data, conception and design, data analysis and interpretation, and manuscript writing; FML: conception and design, and final approval of the manuscript; JMS and WCO: manuscript writing; FSC: final approval of manuscript.


Clinical Trials?

No




Publication History

Received: 10 February 2024

Accepted: 24 June 2024

Article published online:
28 September 2024

© 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution 4.0 International License, permitting copying and reproduction so long as the original work is given appropriate credit (https://creativecommons.org/licenses/by/4.0/)

Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

Bibliographical Record
Tadeu José Fontenele Leite Campos, Felipe Monerrat Lott, Jan Michael Sobel, Walter Carlos Oliveira, Franz Santos Campos. Postchemotherapy Robot-Assisted Retroperitoneal Lymph Node Dissection for Metastatic Testicular Cancer: Initial Experience at a Brazilian Oncology Center. Brazilian Journal of Oncology 2024; 20: s00441790563.
DOI: 10.1055/s-0044-1790563
 

  • References

  • 1 Howlader N, Noone AM, Krapcho M. et al. SEER cancer statistics review, 1975–2014. National Cancer Institute. Bethesda, MD, 2017. https://seer.cancer.gov/csr/1975_2014/ , based on November 2016 SEER data submission, posted to the SEER web site, April 2017
    Google Scholar
  • 2 Rajpert-De Meyts E, McGlynn KA, Okamoto K, Jewett MAS, Bokemeyer C. Testicular germ cell tumours. Lancet 2016; 387 (10029): 1762-1774
    Google Scholar
  • 3 Souza R. . Linfadenectomia retroperitoneal pós-quimioterapia no tratamento do câncer de testículo metastático: a série de casos de um centro oncológico no Brasil. Tese (Pós-graduação em urologia em oncologia) – Instituto Nacional de Câncer, Rio de Janeiro, 2020 :27.
  • 4 Chalfin HJ, Ludwig W, Pierorazio PM, Allaf ME. Robotic primary RPLND for stage I testicular cancer: a review of indications and outcomes. Curr Urol Rep 2016; 17 (05) 41
    Google Scholar
  • 5 Hanna NH, Einhorn LH. Testicular cancer–discoveries and updates. N Engl J Med 2014; 371 (21) 2005-2016
    Google Scholar
  • 6 Rice KR, Beck SD, Bihrle R, Cary KC, Einhorn LH, Foster RS. Survival analysis of pure seminoma at post-chemotherapy retroperitoneal lymph node dissection. J Urol 2014; 192 (05) 1397-1402
    Google Scholar
  • 7 Davol P, Sumfest J, Rukstalis D. Robotic-assisted laparoscopic retroperitoneal lymph node dissection. Urology 2006; 67 (01) 199
    Google Scholar
  • 8 Kamel MH, Littlejohn N, Cox M, Eltahawy EA, Davis R. Post-Chemotherapy robotic retroperitoneal lymph node dissection: institutional experience. J Endourol 2016; 30 (05) 510-519
    Google Scholar
  • 9 Abdul-Muhsin H, Rocco N, Navaratnam A. et al. Outcomes of post-chemotherapy robot-assisted retroperitoneal lymph node dissection in testicular cancer: multi-institutional study. World J Urol 2021; 39 (10) 3833-3838
    Google Scholar
  • 10 Torricelli FCM, Jardim D, Guglielmetti GB, Patel V, Coelho RF. Robot - assisted laparoscopic retroperitoneal lymph node dissection in testicular tumor. Int Braz J Urol 2017; 43 (01) 171
    Google Scholar